Physician profile
Amy Huggins
NPI 1649372434
$1,692.42
in general payments reported to CMS, 2019-2025
15 companies · $342 in 2025
The $342 reported for 2025 was more than what 87% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $131 · 2021: $88.50 · 2022: $228 · 2023: $510 · 2024: $260 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,111.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $460.31 | 2021-2025 | Azstarys |
| Glaxosmithkline, LLC. | $260.24 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Ironshore Pharmaceuticals INC. | $252.27 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $176.46 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $169.22 | 2019-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Collegium Pharmaceutical, INC. | $76.26 | 2025 | Jornay Pm |
| Tris Pharma INC | $74.48 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Supernus Pharmaceuticals, INC. | $67.06 | 2022-2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $35.33 | 2019-2020 | |
| Sanofi Pasteur INC. | $31.99 | 2021-2023 | |
| Seqirus USA INC | $21.78 | 2025 | Flucelvax |
| Ars Pharmaceuticals Operations, INC. | $20.49 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $18.48 | 2019 | |
| Acadia Pharmaceuticals INC | $16.39 | 2024 | Daybue |
| Adlon Therapeutics L.P. | $11.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Huggins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.